Wegovy semaglutide: is it the same thing?
Wegovy semaglutide is a brand of semaglutide for chronic weight management. See how it compares with compounded semaglutide, plus safety and access.
Key facts
- Semaglutide + B12 is $157/month (billed $157 every 4 weeks), charged only after a clinician approves it.
- Answer a few health questions online. A licensed clinician reviews them. If approved, it ships to your door.
- Adults 18 or older. A licensed clinician reviews your health history and decides whether treatment is appropriate for you. Availability depends on the state you live in.
Wegovy (semaglutide) is an FDA approved prescription injection for chronic weight management in certain adults and some adolescents, used with a reduced calorie diet and increased physical activity. If you are comparing brand Wegovy with compounded semaglutide, the key difference is FDA approval and how the medication is made and supplied. Vitals Vault offers compounded semaglutide through clinician guided care, not the brand Wegovy.
- Wegovy semaglutide means Wegovy is a brand of semaglutide for chronic weight management.
- Semaglutide is also the active ingredient in Ozempic, but the products are not interchangeable without a clinician.
- Compounded semaglutide is not Wegovy and is not FDA-approved.
- Common side effects are stomach and bowel related; serious risks include thyroid C-cell tumor warning, pancreatitis and gallbladder disease.
- Cost and coverage vary by insurance rules, supply and required follow up; current prices are shown on this page.
What Wegovy semaglutide is
A brand name medication
Wegovy is the brand name for semaglutide in a single dose injection pen. It is FDA approved for chronic weight management in adults with obesity or overweight with at least one weight related condition, and for certain adolescents with obesity. It is used along with diet and physical activity.
Semaglutide is the ingredient
Semaglutide is the active drug in Wegovy. Semaglutide is also used in other prescription products, including Ozempic for type 2 diabetes. Even when the ingredient is the same, products can differ in approved use, dosing schedule and device.
Compounded semaglutide is different
Compounded semaglutide is prepared by a licensed pharmacy for an individual prescription and is not FDA approved. It is not the same product as Wegovy, and it should not be described as a generic of Wegovy. Your clinician can help you understand what you are being prescribed and why.
What it is approved to treat
Wegovy is approved to reduce excess body weight and maintain weight reduction long term when combined with lifestyle changes. It is also approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.
- Drug class
- GLP-1 receptor agonist (glucagon-like peptide 1)
- Active ingredient
- Semaglutide
- Route
- Subcutaneous injection (under the skin)
- FDA approved product discussed
- Wegovy (semaglutide) injection
How semaglutide works for weight management
Mimics a natural hormone
Semaglutide acts like GLP-1, a hormone your body releases after eating. GLP-1 receptor activation affects appetite and food intake through the brain, and it also slows stomach emptying. These effects can help support reduced calorie intake when paired with lifestyle changes.
Also affects blood sugar
GLP-1 receptor agonists can improve glucose related signals, including stimulating insulin release when blood sugar is high. Even if you do not have diabetes, these effects matter because they can influence side effects and drug interactions, including the risk of low blood sugar when combined with certain diabetes medicines.
Why dose changes are gradual
Wegovy is started at a lower dose and increased over time to reduce stomach related side effects. Your prescribing clinician sets the schedule and adjusts it based on tolerability and response. Do not change your dose or schedule without clinical guidance.
Who Wegovy may be for
Adults with obesity
Wegovy is indicated for chronic weight management in adults with obesity (body mass index, BMI, 30 kg/m2 or greater) as an adjunct to reduced calorie diet and increased physical activity. A clinician confirms whether you meet criteria and whether the benefits outweigh risks for you.
Adults with overweight plus a condition
Wegovy is also indicated for adults with overweight (BMI 27 kg/m2 or greater) who have at least one weight related comorbidity such as hypertension, type 2 diabetes or dyslipidemia. Your clinician will review your medical history, medications and goals before deciding if it fits.
Some adolescents with obesity
Wegovy is indicated for adolescents aged 12 years and older with obesity, used with lifestyle changes. Pediatric use should be managed by a clinician experienced in adolescent weight management and monitoring.
Adults with cardiovascular disease
For adults with established cardiovascular disease and either obesity or overweight, Wegovy is indicated to reduce the risk of major adverse cardiovascular events. This is separate from weight loss goals and requires individualized risk assessment and follow up.
Who should not take Wegovy or semaglutide
Certain thyroid cancer history
Do not use Wegovy if you or a family member has had medullary thyroid carcinoma (MTC), or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This relates to the boxed warning about thyroid C-cell tumors seen in rodents. A clinician can help you assess your personal risk.
Allergy to semaglutide
Do not use Wegovy if you have had a serious hypersensitivity reaction to semaglutide or any ingredient in the product. Seek urgent care for symptoms such as swelling of the face, lips or tongue, trouble breathing, or severe rash after an injection.
Pregnancy considerations
Weight loss is not recommended during pregnancy, and Wegovy is not recommended in pregnancy. If you are trying to conceive, pregnant or breastfeeding, discuss safer alternatives and timing with your clinician.
Certain medication combinations
If you use insulin or a sulfonylurea, adding semaglutide can increase the risk of low blood sugar. Your clinician may need to adjust diabetes medications and monitoring. Always share a full medication list, including over the counter products.
What to expect if you start semaglutide
A gradual titration
Wegovy dosing is increased gradually over several weeks to reduce gastrointestinal side effects. Some people need more time at a given dose due to nausea or vomiting. Your clinician decides the pace and whether to continue, pause or stop based on safety and tolerability.
Lifestyle still matters
Wegovy is intended to be used with a reduced calorie diet and increased physical activity. Many people do best with a plan that includes nutrition, movement and behavior support. Ask your clinician what changes are realistic and safe for you.
Ongoing monitoring
Follow up is important to review side effects, hydration, and how other conditions and medications are affected. If you have diabetes, monitoring is especially important because blood sugar can change. Your clinician may also review kidney function if you have significant vomiting or diarrhea.
Injection device and training
Wegovy is supplied as a single dose pen for subcutaneous injection. Your pharmacist or prescribing clinician should show you how to use the pen, and the Instructions for Use describe the process. If you are prescribed compounded semaglutide, your clinician and dispensing pharmacy provide the administration instructions.
Side effects and warnings
Nausea
Nausea is one of the most common side effects with Wegovy, especially during dose increases. Eating smaller meals, avoiding high fat meals, and staying hydrated may help, but persistent or severe symptoms should be discussed with your clinician. Severe nausea with inability to keep fluids down can lead to dehydration.
Vomiting or diarrhea
Vomiting and diarrhea are common and can be worse early in treatment or after dose escalation. These symptoms can contribute to dehydration, which may worsen kidney problems in susceptible people. Contact a clinician if symptoms are severe, prolonged, or you cannot keep fluids down.
Constipation and abdominal pain
Constipation and abdominal pain are common with semaglutide. Adequate fluids and gradual dietary changes can help some people, but severe or worsening pain should be evaluated. Do not ignore persistent abdominal pain, especially if it is severe.
Thyroid C-cell tumor warning
Wegovy has a boxed warning about the risk of thyroid C-cell tumors based on findings in rodents; it is unknown whether it causes such tumors in humans. Do not use it if you have a personal or family history of medullary thyroid carcinoma or MEN 2. Tell your clinician about a neck lump, hoarseness, trouble swallowing, or shortness of breath.
Pancreatitis
Acute pancreatitis has been reported with GLP-1 receptor agonists, including semaglutide. Seek medical evaluation for severe abdominal pain that may radiate to the back, with or without vomiting. If pancreatitis is suspected, a clinician will decide whether to stop the medication.
Gallbladder disease
Gallbladder problems, including gallstones, have been reported with Wegovy. Symptoms can include right upper abdominal pain, fever, jaundice, or clay colored stools. Contact a clinician promptly if these occur because evaluation and treatment may be needed.
Kidney problems from dehydration
Acute kidney injury has been reported, sometimes in people who had nausea, vomiting or diarrhea leading to dehydration. If you have kidney disease or you develop significant gastrointestinal symptoms, your clinician may recommend closer monitoring and hydration strategies. Seek care if you have reduced urination or feel faint.
Low blood sugar with diabetes meds
Semaglutide can increase the risk of hypoglycemia when used with insulin or insulin secretagogues such as sulfonylureas. Symptoms can include sweating, shakiness, confusion or fast heartbeat. Your clinician may adjust other diabetes medicines and advise on monitoring.
Diabetic retinopathy complications
In people with type 2 diabetes, rapid improvements in blood sugar can be associated with temporary worsening of diabetic retinopathy. If you have diabetes and eye disease, tell your clinician and keep up with eye exams. Report new vision changes promptly.
Allergic reactions
Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported. Stop using the product and seek emergency care for trouble breathing, swelling of the face or throat, or widespread rash. Tell your clinician about any prior reactions to GLP-1 medicines.
Cost and access: what affects what you pay
Brand vs compounded matters
Wegovy is a brand product with FDA approval and manufacturer supply chain, while compounded semaglutide is prepared by a pharmacy for an individual prescription and is not FDA approved. These differences can affect availability, insurance coverage, and out of pocket cost. Current prices for Vitals Vault options are shown on this page.
Insurance coverage varies
Coverage for anti obesity medications depends on your plan, employer benefits, and prior authorization rules. Some plans require documentation of BMI, weight related conditions, and participation in lifestyle programs. A clinician can help provide appropriate medical documentation when indicated.
Supply and pharmacy network
Access can be affected by supply constraints, pharmacy network restrictions, and whether your plan covers the specific product. If you are prescribed a compounded medication, the dispensing pharmacy and shipping rules can also affect timing. Availability depends on the state you live in.
Follow up and monitoring
Many people need follow up visits to manage side effects, adjust the plan, and coordinate care with other conditions like diabetes or high blood pressure. Some clinicians may request recent labs before prescribing, especially if you have metabolic risk factors. These clinical steps can influence total cost of care.
How to get semaglutide safely
- 1
Start with a clinical review
A licensed clinician reviews your health history, goals, and current medications to decide if semaglutide fits.
- 2
Complete any requested labs
A clinician may ask for recent lab results before prescribing, especially if you have metabolic risks.
- 3
Discuss options and safety
Review brand Wegovy versus compounded semaglutide, expected side effects, and warning signs that need urgent care.
- 4
Follow up and adjust
Ongoing check ins help manage tolerability, coordinate other medications, and support long term use when appropriate.
Frequently Asked Questions
Is Wegovy semaglutide?
Yes. Wegovy is the brand name for semaglutide, an FDA approved prescription injection for chronic weight management in certain people. Semaglutide is the active ingredient, but different semaglutide products can have different approved uses and dosing.
Is semaglutide the same as Wegovy?
Semaglutide is the drug ingredient, while Wegovy is a specific brand product that contains semaglutide. Compounded semaglutide is not the same product as Wegovy and is not FDA approved. A clinician can help you compare options safely.
What are the most common side effects of Wegovy (semaglutide)?
The most common side effects are gastrointestinal, including nausea, vomiting, diarrhea, constipation, and abdominal pain. These often happen during dose increases. Contact a clinician if symptoms are severe or you cannot keep fluids down.
Does Wegovy have a boxed warning?
Yes. Wegovy has a boxed warning about the risk of thyroid C-cell tumors based on animal studies, and it should not be used if you have a personal or family history of medullary thyroid carcinoma or MEN 2. Discuss your thyroid history with a clinician before treatment.
How much does Wegovy semaglutide cost?
Cost depends on whether you use brand Wegovy or a compounded semaglutide option, your insurance coverage, and any prior authorization requirements. Supply and follow up care can also affect total cost. Current prices for Vitals Vault options are shown on this page.